Which one of the following drugs is least likely to reduce the risk of cardiovascular disease?

• A. Biguanides
• B. Statins
• C. ACE inhibitors
• D. Antiplatelet agents

Answer: (D)

The key idea is how different drugs impact the underlying processes that drive cardiovascular disease. Statins target a major driver by lowering LDL cholesterol and stabilizing plaques, which reduces atherosclerotic progression and events. ACE inhibitors help by lowering blood pressure, improving endothelial function, and offering vascular protection. Biguanides (metformin) improve insulin sensitivity and glycemic control in diabetes, which translates into lower macrovascular risk for many patients.

Antiplatelet agents, however, mainly prevent thrombosis on existing plaques or after a cardiovascular event rather than altering the underlying atherosclerotic disease itself. In primary prevention, their benefit is modest and often offset by bleeding risks, so they are the least likely to reduce overall cardiovascular disease risk compared with the other drug classes listed.

So, antiplatelet agents are least likely to lower cardiovascular disease risk overall, whereas statins, ACE inhibitors, and metformin have clearer roles in reducing cardiovascular risk through their respective mechanisms.